FDA Approves Sanofi's Enzyme Therapy For Late-Onset Pompe Disease

by Vandana Singh, Benzinga Editor

August 6, 2021 12:31 PM | 1 min read |

The FDA has approved Sanofi's SA SNY Nexviazyme (avalglucosidase alfa-ngpt) to treat patients one year of age and older with late-onset Pompe disease.
Pompe disease is a progressive and debilitating muscle disorder that impairs a person's ability to move and breathe.
Nexviazyme is an enzyme replacement therapy (ERT) designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of enzyme replacement therapy in Pompe disease.
Price Action: SNY shares are up 0.2% at $50.66 during the market session on the last check Friday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech News Health Care FDA General Briefs Pompe Disease

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.